Acumen Pharmaceuticals, Inc.
ABOS
$1.36
-$0.05-3.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -42.21% | 22.50% | -24.82% | -44.93% | -38.08% |
| Total Depreciation and Amortization | 4.44% | 2.27% | -2.22% | 0.00% | 2.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.36% | 19.00% | 20.43% | 663.74% | -82.45% |
| Change in Net Operating Assets | 185.23% | -189.55% | 120.17% | -0.82% | 192.57% |
| Cash from Operations | 6.71% | -25.38% | -10.65% | -48.66% | 7.36% |
| Capital Expenditure | 88.61% | -- | -- | 100.00% | 54.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 33.80% | -3.02% | 392.77% | -126.87% | 510.18% |
| Cash from Investing | 34.14% | -3.28% | 392.77% | -126.88% | 509.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | 100.00% | -711.11% | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 67.19% | -113.33% |
| Cash from Financing | 100.00% | -300.00% | 78.57% | 67.19% | -101.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 221.63% | -324.19% | 107.01% | -265.37% | 205.37% |